AstraZeneca signs potential $240M R&D deal with Alchemia

04/24/2013 | Genetic Engineering & Biotechnology News

Alchemia and AstraZeneca agreed to collaborate in the discovery and potential development of novel small molecules against multiple targets using the former's Diversity Scanning Array and Versatile Assembly on Stable Templates chemistry technology. AstraZeneca will pay Alchemia an undisclosed upfront fee, research funding, and as much as $240 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC